Viking Therapeutics (VKTX) Enterprise Value (2016 - 2025)
Viking Therapeutics (VKTX) has disclosed Enterprise Value for 12 consecutive years, with -$705.7 million as the latest value for Q4 2025.
- Quarterly Enterprise Value rose 21.81% to -$705.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$705.7 million through Dec 2025, up 21.81% year-over-year, with the annual reading at -$705.7 million for FY2025, 21.81% up from the prior year.
- Enterprise Value hit -$705.7 million in Q4 2025 for Viking Therapeutics, up from -$714.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$135.7 million in Q1 2023 to a low of -$963.0 million in Q1 2024.
- Historically, Enterprise Value has averaged -$490.2 million across 5 years, with a median of -$369.2 million in 2023.
- Biggest five-year swings in Enterprise Value: soared 61.35% in 2023 and later plummeted 609.82% in 2024.
- Year by year, Enterprise Value stood at -$202.1 million in 2021, then grew by 23.07% to -$155.5 million in 2022, then crashed by 132.87% to -$362.1 million in 2023, then tumbled by 149.29% to -$902.6 million in 2024, then increased by 21.81% to -$705.7 million in 2025.
- Business Quant data shows Enterprise Value for VKTX at -$705.7 million in Q4 2025, -$714.6 million in Q3 2025, and -$807.7 million in Q2 2025.